Lung Cancer and EGFR Mutations: Divide and Conquer - August 19, 2015

Genomics|Features|Lung Cancer

Lung Cancer

Lung Cancer and EGFR Mutations: Divide and Conquer - August 19, 2015

CDC and Related Info

• What you can do to lower your lung cancer risk
• A family health history of lung cancer is a risk factor for lung cancer
• Genes reported in relation to lung cancer, including genomewide association studies via theHuGE Navigator

NCI Information: With FDA approval, Gefitinib returns to U.S. market for some patients with lung cancer

Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Narita Y et al. Lung Cancer 2015 Jul 26.

Patients with non-small cell lung cancer analyzed for EGFR: Adherence to guidelines, prevalence and outcome.
Sandelin M et al. Anticancer Res. 2015 Jul (7) 3979-85

EGFR mutations in non-small-cell lung cancer: Find, divide, and conquer
Morgensztern D et al, JAMA Oncology, May 2015

Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer.
Mendell J et al. EBioMedicine 2015 Mar (3) 264-71

Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.
Wang T et al. Exp Ther Med 2015 Jun (6) 2095-2103

Predictive biomarkers in precision medicine and drug development against lung cancer.
Fang B et al. Chin J Cancer 2015 (1) 26

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J et al. Health Technol Assess 2015 Jun (47) 1-134

Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance.
Li Xiang-Nan et al. Int J Clin Exp Med 2015 (4) 5397-405

Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma.
Stewart EL et al. J. Clin. Oncol. 2015 Jun 29

Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: Results from a multicenter retrospective study (HANSHIN Oncology Group 0212).
Otsuka T et al. Anticancer Res. 2015 Jul (7) 3885-91

Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL et al. Lung Cancer 2015 Jun 6.

The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
Zhou F et al. Lung Cancer 2015 Jun 17.

Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer.
Baik CS et al. J Thorac Oncol 2015 Jun 23.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu Y-L et al. Ann. Oncol. 2015 Jun 23.

Clinical features and mutation status of EGFR, KRAS, BRAF, EML4-ALK and ROS1 between surgical resection samples and non surgical resection samples in lung cancer.
Li W et al. J Thorac Dis 2015 May (5) 875-80

ERß localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Wang Z et al. Sci Rep 2015 11392

Lung Cancer: Recent Genomics Insights - July 1, 2015

Patients with non-small cell lung cancer analyzed for EGFR: Adherence to guidelines, prevalence and outcome.
Sandelin M et al. Anticancer Res. 2015 Jul 35(7) 3979-85

Lung cancer in the era of precision medicine
Politi K et al. Clin Cancer Res, May 2015

Lung cancer
Gridelli C et al. Nature Reviews Disease Primers, May 2015

EGFR mutations in non-small-cell lung cancer - find, divide, and conquer
Morgensztern D et al. JAMA Oncology, May 2015

A bronchial genomic Classifier for the diagnostic evaluation of lung cancer
Silvestri GA et al. New Engl J Med, May 17, 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne PA et al. N. Engl. J. Med. 2015 Apr 30. (18) 1689-1699

Rociletinib in EGFR-mutated non-small-cell lung cancer.
Sequist LV et al. N. Engl. J. Med. 2015 Apr 30. (18) 1700-1709

Overcoming resistance to targeted therapy for lung cancer.
Govindan R et al. N. Engl. J. Med. 2015 Apr 30. (18) 1760-1761

Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.
Richer AL et al. Pharmgenomics Pers Med 2015 63-79

Genomics driven-oncology: challenges and perspectives.
Normanno N et al. BMC Cancer 2015 141

BRAF mutations in non-small cell lung cancer.
Luk PP et al. Transl Lung Cancer Res 2015 Apr (2) 142-8

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.
Wang S et al. Transl Lung Cancer Res 2015 Apr (2) 119-25

Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing.
Iwakawa R et al. Carcinogenesis 2015 Apr 11.

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Oser MG et al. Lancet Oncol. 2015 Apr (4) e165-e172

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy.
Mok TS et al. Clin. Cancer Res. 2015 Mar 31.

Genetic variants of the MDM2 gene are predictive of treatment-related toxicities and overall survival in patients with advanced NSCLC.
Qian J et al. Clin Lung Cancer 2015 Feb 19.

The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.
Lewandowska MA et al. PLoS ONE 2015 (2) e0117983

Oncologists push beyond new lung cancer genomic testing guidelines.
Garber K et al. J. Natl. Cancer Inst. 2015 Feb (2)

Lung Cancer: Smoking, Genomics and Family Health History - November 6, 2014

CDC information: What you can do to lower your lung cancer risk

CDC information: A family health history of lung cancer is a risk factor for lung cancer

Did you know? 1202 genes have been reported in relation to risk and outcomes of lung cancer, including 74 genomewide association studies. To find out more, visit the HuGE Navigator

American Cancer Society- Why lung cancer strikes nonsmokers- risk factors include genetics

Recent Insights

Common genetic variants on 3q28 contribute to non-small cell lung cancer susceptibility: evidence from 10 case-control studies.
Jin YX, et al. Mol Genet Genomics. 2014 Oct 25

Small cell lung cancer: Where do we go from here?
Byers LA, et al. Cancer. 2014 Oct 21.

Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis.
Ye XH, et al. Mol Genet Genomics. 2014 Oct 22.

Therapeutic use of micrornas in lung cancer.
Fortunato O, et al. Biomed Res Int. 2014;2014:756975. Review

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.
Yap TA, et al. Pharmgenomics Pers Med. 2014 Sep 19;7:285-95.

The expression of four genes as a prognostic classifier for stage I Lung Adenocarcinoma in 12 independent cohorts.
Okayama H, et al. Cancer Epidemiol Biomarkers Prev. 2014 Sep 21

Lung Cancer: Genomic Tests and Improved Outcomes - May 29, 2014

National Cancer Institute: Lung cancer is the leading cause of cancer death in men & women.Here's what you need to know

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Kris MG, et al. JAMA. 2014 May 21;311(19):1998-2006.

Non–small cell lung cancer and precision medicine: A model for the incorporation of genomic features into clinical trial design
Pasche B, et al. JAMA 2014 May 12

Personalized medicine boost lung cancer survival, Phillipa Brice, PHG Foundation, May 23

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
Westwood M, et al. Health Technol Assess 2014 May;18(32):1-166

Find out which genomic tests for lung cancer can improve health and affect survival (tier 1), visit the CDC Table of genomic applications by level of evidence and look for lung cancer entries